CU24426B1 - PROCEDIMIENTO DE PREPARACIÓN DE DERIVADOS DE 5-(1-BENZOTIOFEN-2-IL)PIRROLO[2,1-f][1,2,4]TRIAZIN-4-AMINA Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENE - Google Patents
PROCEDIMIENTO DE PREPARACIÓN DE DERIVADOS DE 5-(1-BENZOTIOFEN-2-IL)PIRROLO[2,1-f][1,2,4]TRIAZIN-4-AMINA Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEInfo
- Publication number
- CU24426B1 CU24426B1 CU2016000039A CU20160039A CU24426B1 CU 24426 B1 CU24426 B1 CU 24426B1 CU 2016000039 A CU2016000039 A CU 2016000039A CU 20160039 A CU20160039 A CU 20160039A CU 24426 B1 CU24426 B1 CU 24426B1
- Authority
- CU
- Cuba
- Prior art keywords
- derivatives
- benzotiofen
- pirrolo
- amina
- triazin
- Prior art date
Links
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- -1 1-benzothiophene-2-yl Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11193841 | 2011-12-15 | ||
| PCT/EP2012/074977 WO2013087578A1 (en) | 2011-12-15 | 2012-12-10 | Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20160039A7 CU20160039A7 (es) | 2016-08-31 |
| CU24426B1 true CU24426B1 (es) | 2019-06-04 |
Family
ID=47326168
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2016000039A CU24426B1 (es) | 2011-12-15 | 2012-12-10 | PROCEDIMIENTO DE PREPARACIÓN DE DERIVADOS DE 5-(1-BENZOTIOFEN-2-IL)PIRROLO[2,1-f][1,2,4]TRIAZIN-4-AMINA Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENE |
| CUP2014000065A CU20140065A7 (es) | 2011-12-15 | 2014-06-09 | DERIVADOS DE 5-(1-BENZOTIOFEN-2-IL) PIRROLO[2,1-f][1,2,4]TRIAZIN-4-AMINA |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2014000065A CU20140065A7 (es) | 2011-12-15 | 2014-06-09 | DERIVADOS DE 5-(1-BENZOTIOFEN-2-IL) PIRROLO[2,1-f][1,2,4]TRIAZIN-4-AMINA |
Country Status (42)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10388493B2 (en) | 2011-09-16 | 2019-08-20 | Lam Research Corporation | Component of a substrate support assembly producing localized magnetic fields |
| UY34484A (es) * | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| TW201536293A (zh) | 2013-07-18 | 2015-10-01 | Taiho Pharmaceutical Co Ltd | 對ｆｇｆｒ抑制劑具耐受性之癌的治療藥 |
| JP6084291B2 (ja) | 2013-07-18 | 2017-02-22 | 大鵬薬品工業株式会社 | Ｆｇｆｒ阻害剤の間歇投与用抗腫瘍剤 |
| WO2015061369A1 (en) * | 2013-10-21 | 2015-04-30 | Genosco | Substituted pyrimidine compounds and their use as syk inhibitors |
| US20180333418A1 (en) * | 2014-12-11 | 2018-11-22 | Bayer Pharma Aktiengesellschaft | Use of pan fgfr inhibitors and method of identifying patients with cancer eligible for treatment with a pan fgfr inhibitor |
| KR20180013851A (ko) * | 2015-03-09 | 2018-02-07 | 바이엘 파마 악티엔게젤샤프트 | 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린-함유 조합물 |
| BR112018012914B1 (pt) | 2015-12-22 | 2023-04-18 | SHY Therapeutics LLC | Composto, uso de um composto e composição farmacêutica |
| EP3424505A4 (en) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| KR102558066B1 (ko) | 2016-03-28 | 2023-07-25 | 인사이트 코포레이션 | Tam 억제제로서 피롤로트리아진 화합물 |
| CN107513068A (zh) * | 2016-06-16 | 2017-12-26 | 中国科学院上海药物研究所 | 一种具有fgfr抑制活性的新型化合物及其制备和应用 |
| CN110300589B (zh) | 2016-12-16 | 2023-03-10 | 囊性纤维化基金会 | 作为cftr增效剂的双环异杂芳基衍生物 |
| AU2018288841B2 (en) | 2017-06-21 | 2022-09-29 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease |
| RU2771311C2 (ru) * | 2017-08-15 | 2022-04-29 | Сиэсписи Чжунци Фармасьютикал Текнолоджи (Шишцзяжуан) Ко., Лтд. | Ингибитор fgfr и его медицинское применение |
| WO2019034075A1 (zh) * | 2017-08-15 | 2019-02-21 | 南京明德新药研发股份有限公司 | Fgfr和egfr抑制剂 |
| IL273579B2 (en) | 2017-09-27 | 2025-10-01 | Incyte Corp | Salts of pyrrolizidine derivatives used as Tm inhibitors. |
| WO2019081346A1 (en) * | 2017-10-25 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | PROCESS FOR THE PREPARATION OF BENZOTHIOPHEN-2YL BORONATE |
| WO2019105734A1 (en) | 2017-11-28 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib |
| TWI790364B (zh) | 2018-03-19 | 2023-01-21 | 日商大鵬藥品工業股份有限公司 | 包含烷基硫酸鈉之醫藥組合物 |
| WO2019180141A1 (en) | 2018-03-23 | 2019-09-26 | Bayer Aktiengesellschaft | Combinations of rogaratinib |
| HRP20250676T1 (hr) | 2018-06-29 | 2025-08-01 | Incyte Corporation | Formulacije inhibitora axl/mer |
| WO2020132071A1 (en) | 2018-12-19 | 2020-06-25 | Shy Therapeutics. Llc | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease |
| US20220098201A1 (en) * | 2019-01-31 | 2022-03-31 | Bayer Aktiengesellschaft | The monohydrate of rogaratinib hydrochloride and solid states thereof |
| CA3130247C (en) * | 2019-02-15 | 2024-02-13 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Fgfr inhibitor compound in solid form and preparation method therefor |
| WO2020170355A1 (ja) * | 2019-02-20 | 2020-08-27 | 大鵬薬品工業株式会社 | Ｆｇｆｒ１変異腫瘍の治療方法 |
| CN109928976A (zh) * | 2019-02-26 | 2019-06-25 | 泰州亿腾景昂药业有限公司 | 一种工业化生产eoc317的方法 |
| CN119874707A (zh) * | 2019-05-13 | 2025-04-25 | 传达治疗有限公司 | Fgfr抑制剂和其使用方法 |
| WO2021089005A1 (zh) * | 2019-11-08 | 2021-05-14 | 石药集团中奇制药技术（石家庄）有限公司 | 一种fgfr抑制剂的用途 |
| CN111004234A (zh) * | 2019-11-28 | 2020-04-14 | 湖南农业大学 | 一种2-苯基咪唑并[1,2-α]吡啶类化合物的C3位卤化方法 |
| CN115697343A (zh) | 2020-03-06 | 2023-02-03 | 因赛特公司 | 包含axl/mer和pd-1/pd-l1抑制剂的组合疗法 |
| CN117402161A (zh) * | 2022-07-06 | 2024-01-16 | 上海科恩泰生物医药科技有限公司 | 一种具有fgfr抑制作用的亚砜亚胺类化合物、包含其的药物组合物及其用途 |
| KR20250164828A (ko) | 2023-03-30 | 2025-11-25 | 레볼루션 메디슨즈, 인크. | Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL204437B1 (pl) | 1999-05-21 | 2010-01-29 | Bristol Myers Squibb Co | Pochodna pirolotriazyny i jej zastosowanie oraz kompozycja farmaceutyczna i jej zastosowanie |
| WO2001019828A2 (en) | 1999-09-17 | 2001-03-22 | Basf Aktiengesellschaft | Kinase inhibitors as therapeutic agents |
| JPWO2004096806A1 (ja) * | 2003-04-30 | 2006-07-13 | 大日本住友製薬株式会社 | 縮合イミダゾール誘導体 |
| DE10327439A1 (de) * | 2003-06-18 | 2005-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| MXPA06011423A (es) | 2004-04-02 | 2007-01-23 | Osi Pharm Inc | Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico. |
| UY28931A1 (es) | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
| TW200635927A (en) * | 2004-12-22 | 2006-10-16 | Bristol Myers Squibb Co | Synthetic process |
| WO2007056170A2 (en) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| US7700594B2 (en) * | 2005-11-17 | 2010-04-20 | Osi Pharmaceuticals, Inc. | Fused bicyclic mTOR inhibitors |
| US7514435B2 (en) | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| EP1957485B1 (en) | 2005-12-02 | 2013-02-13 | Bayer HealthCare, LLC | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| CA2631732C (en) | 2005-12-02 | 2012-12-18 | Bayer Healthcare Llc | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase |
| PE20070855A1 (es) * | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
| CN101389630A (zh) * | 2005-12-29 | 2009-03-18 | 艾博特公司 | 蛋白激酶抑制剂 |
| US8124759B2 (en) | 2007-05-09 | 2012-02-28 | Abbott Laboratories | Inhibitors of protein kinases |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| WO2010126960A1 (en) | 2009-04-29 | 2010-11-04 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
| UY34484A (es) * | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
-
2012
- 2012-12-03 UY UY0001034484A patent/UY34484A/es unknown
- 2012-12-10 HU HUE12798738A patent/HUE029582T2/en unknown
- 2012-12-10 EA EA201400707A patent/EA029556B1/ru not_active IP Right Cessation
- 2012-12-10 LT LTEP12798738.6T patent/LT2791140T/lt unknown
- 2012-12-10 KR KR1020147019406A patent/KR102057444B1/ko not_active Expired - Fee Related
- 2012-12-10 PT PT127987386T patent/PT2791140T/pt unknown
- 2012-12-10 PE PE2014000926A patent/PE20141855A1/es active IP Right Grant
- 2012-12-10 PL PL12798738T patent/PL2791140T3/pl unknown
- 2012-12-10 SG SG11201402325QA patent/SG11201402325QA/en unknown
- 2012-12-10 ES ES12798738.6T patent/ES2591203T3/es active Active
- 2012-12-10 MX MX2014006905A patent/MX367158B/es active IP Right Grant
- 2012-12-10 CN CN201280069882.6A patent/CN104245700B/zh not_active Expired - Fee Related
- 2012-12-10 BR BR112014014531-8A patent/BR112014014531B1/pt not_active IP Right Cessation
- 2012-12-10 CA CA2859133A patent/CA2859133C/en active Active
- 2012-12-10 DK DK12798738.6T patent/DK2791140T3/en active
- 2012-12-10 WO PCT/EP2012/074977 patent/WO2013087578A1/en not_active Ceased
- 2012-12-10 JP JP2014546445A patent/JP6050829B2/ja not_active Expired - Fee Related
- 2012-12-10 MY MYPI2014701550A patent/MY178660A/en unknown
- 2012-12-10 SI SI201230702A patent/SI2791140T1/sl unknown
- 2012-12-10 CU CU2016000039A patent/CU24426B1/es unknown
- 2012-12-10 EP EP12798738.6A patent/EP2791140B1/en active Active
- 2012-12-10 ME MEP-2016-181A patent/ME02517B/me unknown
- 2012-12-10 UA UAA201407930A patent/UA116768C2/uk unknown
- 2012-12-10 AU AU2012350750A patent/AU2012350750B2/en not_active Ceased
- 2012-12-10 IN IN4310CHN2014 patent/IN2014CN04310A/en unknown
- 2012-12-10 RS RS20160733A patent/RS55144B1/sr unknown
- 2012-12-10 US US14/365,424 patent/US20140336173A1/en not_active Abandoned
- 2012-12-10 HR HRP20161130TT patent/HRP20161130T1/hr unknown
- 2012-12-12 AR ARP120104679A patent/AR089207A1/es unknown
- 2012-12-12 JO JOP/2012/0377A patent/JO3295B1/ar active
- 2012-12-14 US US13/715,553 patent/US9206184B2/en active Active
- 2012-12-14 TW TW101147336A patent/TWI567076B/zh not_active IP Right Cessation
-
2014
- 2014-05-14 IL IL232611A patent/IL232611A/en active IP Right Grant
- 2014-06-09 CU CUP2014000065A patent/CU20140065A7/es unknown
- 2014-06-09 CO CO14123802A patent/CO7030961A2/es unknown
- 2014-06-10 DO DO2014000127A patent/DOP2014000127A/es unknown
- 2014-06-11 TN TNP2014000255A patent/TN2014000255A1/en unknown
- 2014-06-12 CL CL2014001547A patent/CL2014001547A1/es unknown
- 2014-06-12 EC ECIEPI20144722A patent/ECSP14004722A/es unknown
- 2014-06-13 PH PH12014501355A patent/PH12014501355A1/en unknown
- 2014-06-13 GT GT201400113A patent/GT201400113A/es unknown
- 2014-06-17 CR CR20140288A patent/CR20140288A/es unknown
- 2014-07-14 ZA ZA2014/05140A patent/ZA201405140B/en unknown
-
2016
- 2016-08-31 CY CY20161100853T patent/CY1118112T1/el unknown
-
2017
- 2017-07-17 AU AU2017206140A patent/AU2017206140A1/en not_active Abandoned
-
2018
- 2018-02-20 US US15/900,725 patent/US20190016724A1/en not_active Abandoned
-
2019
- 2019-06-18 AU AU2019204255A patent/AU2019204255A1/en not_active Abandoned
-
2021
- 2021-11-01 US US17/516,542 patent/US20220153745A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24426B1 (es) | PROCEDIMIENTO DE PREPARACIÓN DE DERIVADOS DE 5-(1-BENZOTIOFEN-2-IL)PIRROLO[2,1-f][1,2,4]TRIAZIN-4-AMINA Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENE | |
| EA201391682A1 (ru) | Замещенные производные индазола, активные в качестве ингибиторов киназы | |
| CY1121882T1 (el) | Αναστολεις πυραζολυλο κινοξαλινο κινασης | |
| GB201205669D0 (en) | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof | |
| EA201391416A1 (ru) | Новые соединения в качестве модуляторов протеинкиназ | |
| MX2017006366A (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa. | |
| BR112013018515A2 (pt) | derivados de pirrol tricíclico, processo para preparação e seu uso como inibidores da quinase | |
| BR112014007622A2 (pt) | inibidores de flt3 cinase macrocíclicos | |
| MX2016012097A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer. | |
| HK1203927A1 (en) | Heterocyclic compounds and uses as anticancer agents | |
| CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| EA201270730A1 (ru) | ИНГИБИТОРЫ КИНАЗЫ Cdc7 И ИХ ПРИМЕНЕНИЕ | |
| MX339937B (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit. | |
| PH12014500351B1 (en) | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | |
| EA201290209A1 (ru) | Новые модуляторы бензопиран киназы | |
| MX336051B (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
| EA201500182A1 (ru) | 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ | |
| MX2012000166A (es) | Compuestos de quinazolina que contienen fosforo y metodos de uso de los mismos. | |
| EA201590183A1 (ru) | Производные азаиндола, выступающие в качестве ингибиторов pi3k | |
| EA201390520A1 (ru) | Замещенные соединения пиридазинкарбоксамида | |
| CL2012003637A1 (es) | Compuestos derivados de quinazolina o triazolopiridina sustituidos, inhibidores selectivos de tirosina quinasa; medicamento; composicion farmaceutica; y su uso para tratar, prevenir o mejorar edema retiniano/macular, degeneración macular relacionada con la edad y derrame vascular retiniano relacionado con isquemia, entre otras. | |
| EA201692255A1 (ru) | Улучшенные формы селективного ингибитора pi3k-дельта для применения в фармацевтических препаратах | |
| BR112013025236A2 (pt) | derivados de tieno [2,3-d)pirimidina e seu uso no tratamento de arritmia | |
| NI201200162A (es) | Inhibidores de pirazolil quinoxalina cinasa | |
| CL2011002437A1 (es) | Compuestos derivados de quinoxalina; composicion farmaceutica que los comprende; proceso de preparacion de la composicion y su uso en el tratamiento de trastornos tumoraales. pct fase nacional. |